Bioventix Plc Director Dealing

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or "the Company") 
 
                               Director Dealing 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that it has been notified that Bruce Hiscock, 
Chief Financial Officer of the Company, completed the following dealings in the 
Company's ordinary shares of 5 pence in the Company ("Ordinary Shares"): 
 
  * the transfer, via sale and purchase, of 204 Ordinary Shares into his ISA. 
    Mr Hiscock sold 204 Ordinary Shares at a price of £33.41 from an account in 
    his own name and bought 204 Ordinary Shares at a price of £34.00 to be held 
    in his ISA; and 
  * the additional purchase of 276 Ordinary Shares at a price of £34.00 into 
    his ISA. 
 
Following these transactions, Mr Hiscock's total beneficial interest in the 
Company is now 700 Ordinary Shares, representing approximately 0.01 per cent. 
of the Company's total issued share capital. 
 
For further information please contact: 
 
Bioventix plc                                                Tel: 01252 728 001 
Peter Harrison                 Chief Executive Officer 
 
finnCap Ltd                                                  Tel: 020 7220 0500 
Geoff Nash/Simon Hicks/Abigail Corporate Finance 
Kelly                          ECM 
Alice Lane 
 
 
 
1.     Details of the person discharging managerial responsibilities / person 
       closely associated 
 
a)     Name                     Bruce Hiscock 
 
2.     Reason for the Notification 
 
a)     Position/status          Chief Financial Officer 
 
b)     Initial notification/    Initial notification 
       Amendment 
 
3.     Details of the issuer, emission allowance market participant, auction 
       platform, auctioneer or auction monitor 
 
a)     Name                     Bioventix plc 
 
b)     LEI                      213800225MHX7LZQY108 
 
4.     Details of the transaction(s): section to be repeated for (i) each type 
       of instrument; (ii) each type of transaction; (iii) each date; and (iv) 
       each place where transactions have been conducted 
 
a)     Description of the       Ordinary Shares 
       Financial instrument, 
       type of instrument 
 
       Identification code      GB00B4QVDF07 
 
b)     Nature of the            Sale of Ordinary Shares 
       transaction 
 
c)     Price(s) and volume(s)   Volume(s)            Prices (pence) 
 
                                204                  3,341 
 
d)     Aggregated information:  Sale of 204 Ordinary Shares at a price of 3,341p 
       ·Aggregated volume       per Ordinary Share 
       ·Price 
 
e)     Date of the transaction  26 October 2022 
 
f)     Place of the transaction London Stock Exchange, AIM Market (XLON) 
 
 
 
1.     Details of the person discharging managerial responsibilities / person 
       closely associated 
 
a)     Name                     Bruce Hiscock 
 
2.     Reason for the Notification 
 
a)     Position/status          Chief Financial Officer 
 
b)     Initial notification/    Initial notification 
       Amendment 
 
3.     Details of the issuer, emission allowance market participant, auction 
       platform, auctioneer or auction monitor 
 
a)     Name                     Bioventix plc 
 
b)     LEI                      213800225MHX7LZQY108 
 
4.     Details of the transaction(s): section to be repeated for (i) each type 
       of instrument; (ii) each type of transaction; (iii) each date; and (iv) 
       each place where transactions have been conducted 
 
a)     Description of the       Ordinary Shares 
       Financial instrument, 
       type of instrument 
 
       Identification code      GB00B4QVDF07 
 
b)     Nature of the            Purchase of Ordinary Shares 
       transaction 
 
c)     Price(s) and volume(s)   Volume(s)            Prices (pence) 
 
                                480                  3,400 
 
d)     Aggregated information:  Purchase of 480 Ordinary Shares at a price of 
       ·Aggregated volume       3,400p per Ordinary Share 
       ·Price 
 
e)     Date of the transaction  26 October 2022 
 
f)     Place of the transaction London Stock Exchange, AIM Market (XLON) 
 
 
 
END

(END) Dow Jones Newswires

October 27, 2022 02:00 ET (06:00 GMT)

Bioventix (AQSE:BVXP.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024